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Abstract
Censored survival data are common in clinical trial studies. We propose a unified
framework for sensitivity analysis to censoring at random in survival data using mul-
tiple imputation and martingale, called SMIM. The proposed framework adopts the
δ-adjusted and control-based models, indexed by the sensitivity parameter, entailing
censoring at random and a wide collection of censoring not at random assumptions.
Also, it targets for a broad class of treatment effect estimands defined as functionals
of treatment-specific survival functions, taking into account of missing data due to
censoring. Multiple imputation facilitates the use of simple full-sample estimation;
however, the standard Rubin’s combining rule may over estimate the variance for
inference in the sensitivity analysis framework. We decompose the multiple impu-
tation estimator into a martingale series based on the sequential construction of
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the estimator and propose the wild bootstrap inference by resampling the martin-
gale series. The new bootstrap inference has a theoretical guarantee for consistency
and is computationally efficient compared to the non-parametric bootstrap coun-
terpart. We evaluate the finite-sample performance of the proposed SMIM through
simulation and applications on HIV and cardiovascular clinical trials.
Keywords: Delta adjustment; jump-to-reference; restrictive mean time loss; restrictive
mean survival time; wild-bootstrap.
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1 Introduction
Censored survival outcomes are common in clinical trial research of chronic diseases,
such as respiratory, cardiovascular, cancer, and infectious diseases. As in the missing
data literature, three assumptions about the censoring mechanism have been proposed:
censoring completely at random (CCAR), censoring at random (CAR), and censoring
not at random (CNAR) (Tsiatis, 2006). Censoring due to administrative constraints,
e.g., the planned end of the study, is unrelated to the study treatment or the underlying
health condition. Therefore, the event times are likely to be CCAR. On the other hand,
the censored event times due to non-administrative reasons such as premature dropout
are unlikely to be CCAR. For example, subjects may withdraw from the study because
of adverse events. Common survival analysis methods assume CAR that the censoring
process is independent of the event times conditional on observed covariates; i.e., the
censoring process is explainable by observed information. This assumption will be violated
if sicker subjects are more likely to withdraw from the study, even after accounting for
their observed history, leading to CNAR. Unfortunately, the censoring assumptions are
not commonly testable from the observed data (Rubin, 1976). Inappropriate assumptions
may lead to biased and misleading conclusions. In such settings, regulatory agencies,
such as the FDA, and national research council (NRC, National Research Council, 2010)
request or recommend sensitivity analyses to assess the robustness of study conclusions
to unverifiable assumptions.
In this article, we distinguish different reasons for censoring including administrative
reasons and non-administrative reasons. For the latter, we consider patient premature
dropout, which could be a case of CNAR. The δ-adjusted and control-based models are
pattern mixture models (Little, 1993) that are flexible to accommodate sensitivity analy-
sis to unverifiable missing data assumptions by introducing sensitivity parameters. Due to
the transparency, these models have been widely used in applied statistics to handle miss-
ing data (e.g., National Research Council, 2012, Ratitch et al., 2013, and Lipkovich et al.,
2016). We consider a class of δ-adjusted/control-based Cox models for censoring due to
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premature dropout, indexed by sensitivity parameter δ. Here, δ is a parameter compar-
ing the outcome distribution of the subjects after non-administrative censoring with the
outcome distribution of the same subjects had they remained on study. Although we
consider the two reasons for censoring, our framework extends readily to multiple reasons
by adopting different δ’s for different groups.
Another important question arises regarding the estimand of interest for treatment
comparison in the presence of missing data. Following the International Council for Har-
monization (ICH) E9 (R1) addendum, estimands should be clearly defined which describe
the quantity to be estimated including how to handle intercurrent events such as prema-
ture dropout (ICH, 2019). In this article, we consider a de facto or treatment policy
strategy, which evaluates treatment effect for all randomized patients on time to event
endpoint regardless of the deviation of treatment such as taking rescue medication or
treatment switch. When time to event data are censored due to premature dropout, the
primary analysis often assume CAR. Throughout this article, we consider the de facto
estimand under the treatment policy strategy, and the true estimand parameter for the
sensitivity analysis can be different after taking into account the likely attenuation of the
treatment effect after dropout. For survival sensitivity analysis using δ-adjusted models,
Lipkovich et al. (2016) considered a marginal Cox proportional hazards parameter, an
additional structural assumption entailing a constant ratio of the hazard rates between
the treatment groups. However, this parameter may be misleading (Herna´n, 2010) if the
proportional hazards assumption is violated as in the δ-adjusted models. Alternatively,
we consider a broad class of treatment effect estimands defined as functionals of the sur-
vival functions, such as the restricted mean survival time (RMST, Chen and Tsiatis, 2001;
Royston and Parmar, 2013; Zhao et al., 2016), i.e., the expectation of survival time re-
stricted to a finite time τ . Instead of focusing on a constant hazards ratio, the RMST
provides a time-evolving profile of survival times for evaluating the treatment effect, with-
out requiring additional model assumptions.
To implement sensitivity analysis, multiple imputation (MI, Rubin, 1987) is the most
popular method. It consists of three steps: first, fill the missing values by plausible values
4
to create multiple complete datasets; second, apply standard full-sample methods to an-
alyze the multiple imputed datasets; and third, use Rubin’s combining rule to summarize
the results for inference. Because of its intuitive appeal, MI is recommended by the NRC
as one of its preferred approaches of addressing missing data (National Research Council,
2012). Indeed, MI provides a valuable tool to handle missing data arising from clin-
ical trials; however, a major challenge arises for inferences. Many studies have real-
ized that Rubin’s variance estimator is not always consistent for general purposes (e.g.,
Yang and Kim, 2016). A sufficient condition for the validity of the MI inference is the
congeniality condition (Meng, 1994). Roughly speaking, it requires the imputation model
to be correctly specified and the subsequent analysis to be compatible with the imputation
model. Even with a correctly specified imputation model, Yang and Kim (2016) showed
that MI is not necessarily congenial for the method of moments estimation, so some
common statistical procedures may be incompatible with MI. This phenomenon becomes
pronounced for adopting MI for general sensitivity analysis in clinical trials. Lu et al.
(2015) and Liu and Pang (2016) demonstrated that Rubin’s combining rule is often con-
servative in control-based imputation. To overcome the conservative of Rubin’s combining
rule, several authors suggested the non-parametric bootstrap to obtain the standard er-
rors (Lu et al., 2015; Gao et al., 2017); however, the non-parametric bootstrap requires
repeating imputation and analysis for all bootstrap samples and therefore causes huge
computation burden.
In this article, we propose a unified framework of survival sensitivity analysis via MI.
Specifically, the missing data is imputed by a δ-adjusted or control-based Cox model for
each treatment group. We derive a novel martingale representation of the proposed MI
estimator. The martingale representation is inspired by the sequential construction of
the MI estimator, namely, model parameter estimation and imputations. This new repre-
sentation invokes the easy-to-implement wild-bootstrap inference. In contrast to Rubin’s
combining rule, the wild-bootstrap inference has a theoretical guarantee for consistency.
Moreover, unlike the non-parametric bootstrap, we do not require repeating imputation
and analysis for the bootstrap resamples and therefore largely reduce the computation
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burden. The new SMIM (Survival sensitive analysis using Multiple Imputation and
M artingale) framework is fairly flexible to accommodate a wide collection of censoring
assumptions and treatment effect estimands.
The rest of this paper proceeds as follows. Section 2 introduces notation, estimands,
MI, and an outline of the proposed SMIM framework. Section 3 presents sensitivity anal-
ysis using the δ-adjusted and control-based Cox models via MI. Section 4 derives the
martingale representation of the MI estimator and the wild bootstrap inference. Section
5 uses simulation to evaluate the finite-sample properties of the estimators, and Section
6 applies the novel estimator to two clinical trials. Section 7 concludes. The supple-
mentary material contains the proofs. An open source R package smim is available at
https://github.com/elong0527/smim.
2 Setup
2.1 Notation and estimands
Without loss of generality, we focus on randomized clinical trials that compare a new
treatment to a control treatment. We assume that the subjects constitute a random
sample from a larger population. Let Xi be a vector of covariates for subject i, and let Ai
be a binary treatment, 1 for the active treatment and 0 for the control treatment. Let Ti
and Ci denote the time to a clinical event and the time to censoring, respectively. The full
set of variables is Fi = (Xi, Ai, Ti, Ci). In the presence of censoring, denote Ui = Ti ∧ Ci,
where ∧ represents the minimal of two values, and Ii = 1(Ti ≤ Ci), where 1(·) is the
indicator function taking value 1 if its argument is true and 0 otherwise. To distinguish
different reasons for censoring, denote Ri = 1 if censoring is due to administrative reasons
and Ri = 2 if censoring is due to premature dropout. Extension to more than two reasons
is straightforward at the expense of heavier notation. The observed set of variables is
Oi = {Xi, Ai, Ui, Ii, (1− Ii)Ri}. We use O1:k to denote the k copies {O1, . . . , Ok}. For the
total of n subjects, let n1 =
∑n
i=1Ai and n0 =
∑n
i=1(1−Ai). For notational convenience,
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let the treated subjects be indexed by i = 1, . . . , n1, and let the control subjects be indexed
by i = n1 + 1, . . . , n.
For treatment comparison, define λa(t) = limh→0 h
−1
P (t ≤ T < t + h | T ≥ t, A = a)
and Sa(t) = P(T ≥ t | A = a) as the treatment-specific hazard rate and survival func-
tion at time t, respectively, for a = 0, 1. Under a proportional hazards assumption
(Herna´n et al., 2000), one can focus on estimating log hazards ratio β = log{λ1(t)/λ0(t)}.
However, the proportional hazards assumption may be problematic, especially when two
survival curves cross. In particular, in sensitivity analysis, the hazard ratios are con-
structed to be different before and after patient dropout and hence the proportional
hazards assumption is violated. In this case, β represents the overall average of the log
hazard ratios over a certain time period, which varies as the time period changes (Herna´n,
2010). Thus, β lacks a clear interpretation.
Alternatively, we focus on treatment effect estimands defined as functionals of treatment-
specific survival distributions. Denote such a functional as ∆τ = Ψτ{S1(t), S0(t)}, which
may depend on some pre-specified constant τ . This formulation covers a broad class of
estimands favored in the context of non-proportional hazards.
Example 1 (Treatment effect estimands) With a proper choice of Ψτ (·), ∆τ repre-
sents the following measures of treatment effect:
a) the difference in survivals at a fixed time point τ , ∆τ = S1(τ)− S0(τ);
b) the difference of treatment-specific τ -RMSTs (restrictive mean survival times) ∆τ =
µ1,τ − µ0,τ , where µa,τ =
´ τ
0
Sa(t)dt for a = 0, 1;
c) the difference of weighted τ -RMSTs ∆τ =
´ τ
0
ω(t){S1(t)− S0(t)}dt, where the non-
negative weight function ω(t) provides differentiable importance at different times;
d) the ratio of τ -RMTLs (restrictive mean time lost) ∆τ = {τ −
´ τ
0
S1(t)dt}/{τ −´ τ
0
S0(t)dt};
e) the difference of τ th quantiles (e.g., medians) of survivals ∆τ = q1,τ − q0,τ , where
qa,τ = infq{Sa(q) ≤ τ}.
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2.2 Simple full-sample estimator and asymptotic linearity
If the event times are fully observed, standard full-sample estimators can apply. To
estimate Sa(t), a simple estimator is the sample proportion Sˆa,n(t) = n
−1
a
∑n
i=1 1(Ai =
a)1(Ti ≥ t), for a = 0, 1. Then, a plug-in estimator of ∆τ is ∆ˆτ,n = Ψτ{Sˆ1,n(t), Sˆ0,n(t)}.
To establish a unified framework, it is important to note that ∆ˆτ,n is asymptotically
linear for all estimands given in Example 1. Under mild regularity conditions, we have
∆ˆτ,n −∆τ =
1∑
a=0
ˆ τ
0
ψa(t)
{
Sˆa,n(t)− Sa(t)
}
dt+ op(n
−1/2), (1)
for bounded variation functions ψa(·).
Example 2 (Asymptotic linear characterization) For all estimands in Example 1,
the full-sample estimators have the following asymptotic linear characterizations.
a) For the difference in the survivals at a fixed time point τ , ∆ˆτ,n = Sˆ1,n(τ)− Sˆ0,n(τ),
corresponding to (1) with ψ1(t) = −ψ0(t) = 1(t = τ).
b) For the difference of the treatment-specific τ -RMSTs, ∆ˆτ,n =
´ τ
0
{
Sˆ1,n(t)− Sˆ0,n(t)
}
dt,
corresponding to (1) with ψ1(t) = −ψ0(t) = 1.
c) For the difference of weighted τ -RMSTs, ∆ˆτ,n =
´ τ
0
ω(t)
{
Sˆ1,n(t)− Sˆ0,n(t)
}
dt, cor-
responding to (1) with ψ1(t) = −ψ0(t) = ω(t).
d) For the ratio of τ -RMTLs, ∆ˆτ,n =
{
τ −
´ τ
0
Sˆ1,n(t)dt
}
/
{
τ −
´ τ
0
Sˆ0,n(t)dt
}
, cor-
responding to (1) with ψ1(t) = −{τ −
´ τ
0
S0,n(u)du}−1 and ψ0(t) = −∆τ{τ −´ τ
0
S0,n(u)du}−1.
e) For ∆τ = q1,τ−q0,τ , ∆ˆτ,n = qˆ1,τ− qˆ0,τ , where qˆa,τ = infq{Sˆa,n(q) ≤ τ}, corresponding
to (1) with ψ1(t) = {S˙1(q1,τ )}−11(t = q1,τ ) and ψ0(t) = −{S˙0(q0,τ )}−11(t = q0,τ ),
where S˙a(q) = dSa(q)/dq.
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For the ratio-type estimator in d), the asymptotic linear characterization can be ob-
tained by the Taylor expansion. For the quantiles in e), under certain regularity conditions
(e.g., Francisco and Fuller, 1991), we can express qˆa,τ as
qˆa,τ − qa,τ =
Sˆa,n(qa,τ )− Sa(qa,τ )
S˙a(qa,τ )
+ oP (n
−1/2). (2)
Expression (2) is called the Bahadur-type representation for qˆa,τ . Then, the asymptotic
linear characterization in e) follows.
2.3 MI
To facilitate applying full-sample estimators, MI creates multiple complete datasets by
filling in missing values. MI proceeds as follows.
Step MI-1. Createm complete datasets by filling in missing times to event with imputed
values generated from an imputation model. Specifically, to create the jth imputed
dataset, generate T
∗(j)
i from the imputation model for each missing Ti. Further
discussions on the imputation models are provided in Section 3.
Step MI-2. Apply a full-sample estimator of ∆τ to each imputed dataset. Denote the
point estimator applied to the jth imputed dataset by ∆ˆ
(j)
τ , and the variance esti-
mator by Vˆ (j).
Step MI-3. Use Rubin’s combining rule to summarize the results from the multiple
imputed datasets. The MI estimator of ∆τ is ∆ˆτ,mi = m
−1
∑m
j=1 ∆ˆ
(j)
τ , and Rubin’s
variance estimator is
Vˆmi(∆ˆτ,mi) =
m+ 1
(m− 1)m
m∑
j=1
(∆ˆ(j)τ − ∆ˆτ,mi)
2 +
1
m
m∑
j=1
Vˆ (j). (3)
It is well known that Rubin’s combining rule may overestimate the variance of the MI
estimator when the full-sample estimators are not self-efficient. To see the problem,
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consider the following decomposition ∆ˆτ,mi − ∆τ = (∆ˆτ,mi − ∆ˆτ,n) + (∆ˆτ,n − ∆τ ), and
therefore the variance of ∆ˆτ,mi is
V(∆ˆτ,mi) = V
(
∆ˆτ,mi − ∆ˆτ,n
)
+ V
(
∆ˆτ,n
)
+ 2cov
(
∆ˆτ,mi − ∆ˆτ,n, ∆ˆτ,n
)
.
The two terms in Rubin’s variance estimator (3) estimate V(∆ˆτ,mi − ∆ˆτ,n) and V(∆ˆτ,n),
respectively. It presumes the covariance term is zero, which, however, is not true in
general. In this case, Rubin’s combining rule is not consistent. Lu et al. (2015) and
Liu and Pang (2016) demonstrated this issue in the sensitivity analysis using control-
based imputation.
We provide an alternative decomposition of the MI estimator, which invokes the wild
bootstrap for consistent variance estimation for general imputation models and estimands.
Before we delve into the technical details, we provide an outline of the proposed SMIM
framework below.
2.4 Outline of the proposed SMIM framework
In Step MI-1, we consider a flexible class of δ-adjusted and control-based Cox imputation
models for sensitivity analysis. For example, the δ-adjusted Cox model assumes the
treatment-specific hazard rate of failing at time t is λa(t | Xi) without premature dropout
and δλa(t | Xi) after dropout, for a = 0, 1. Importantly, under the δ-adjusted Cox model,
we do not impose the restrictive proportional hazards assumption on the treatment effect.
More details will be provided in Section 3.
Based on the MI with Rubin’s combining rule in Step MI-3, the variance estimator
overestimates the true variance of ∆ˆτ,mi. For rectification, we propose a wild bootstrap
variance estimator (Wu, 1986; Liu, 1988) to replace Rubin’s combining rule; Theorem 2 in
Section 4 shows that the proposed variance estimator is consistent for general imputation
models and treatment effect estimands. The consistency ensures the confidence intervals
have proper coverage properties. The wild bootstrap procedure does not require to repeat
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the missing data imputation step (i.e., Step MI-1) and recalculate the point estimator (i.e.,
Step MI-2) using resampling data, therefore it is computationally efficient compared with
the naive bootstrap.
The wild bootstrap variance estimator is motivated by a novel martingale representa-
tion of the MI estimator. Specifically, we show in Section 3 that the MI estimator of ∆τ
can be represented as
n1/2(∆ˆτ,mi −∆τ ) =
(1+m)n∑
k=1
ξn,k + op(1),
where the series {
∑k
i=1 ξn,i, 1 ≤ k ≤ (1 +m)n} along with properly defined σ-fields is a
martingale array. This representation invokes the wild bootstrap procedure that provides
valid variance estimation and inference of the MI estimator of ∆τ (Pauly, 2011).
3 Delta-adjusted and control-based models
To motivate the imputation models for sensitivity analysis, we first consider the CAR
assumption that Ci ⊥⊥ Ti | (Ai, Xi). Under CAR, we have
λa(t | Xi) = lim
h→0
h−1P (t ≤ Ti < t + h | Ti ≥ t, Xi, Ai = a)
= lim
h→0
h−1P (t ≤ Ui < t + h, Ii = 1 | Ui ≥ t, Xi, Ai = a) ,
for a = 0, 1. From λa(t | Xi), we can derive the survival function for the subject i as
Sa(t | Xi) = exp{−
´ t
0
λa(u | Xi)du}. For regularity, we impose a positivity condition for
Sa(t | Xi).
Assumption 1 (Positivity) There exists a constant c such that with probability one,
Sa(t | Xi) ≥ c > 0 for t in [0, τ ] and a = 0, 1.
Following most of the survival analysis literature (e.g., Chen and Tsiatis, 2001), we
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posit a conditional treatment-specific hazard function given covariate Xi; i.e.,
λa(t | Xi) = λa(t)e
βTa Xi , (4)
where λa(t) is an unknown baseline hazard function and βa is a vector of unknown pa-
rameters for a = 0, 1. Importantly, under model (4), we do not impose the restrictive
proportional hazards assumption on the treatment effect because both λa(t) and βa can
be different for the two treatment groups. Other flexible survival models can also be
considered (e.g., Zeng and Lin, 2007; Yin et al., 2008). Let θ = {λa(·), βa : a = 0, 1}
summarize the infinite-dimensional parameter in the Cox model. Under CAR, we can
estimate θ from the standard software such as “coxph” in R (R Development Core Team,
2012) .
We adopt the counting process framework (Andersen and Gill, 1982) to introduce the
estimators and their large sample properties. Define the counting process Ni(t) = 1(Ui ≤
t, Ii = 1) of observing the event and the at-risk process Yi(t) = 1(Ui ≥ t). Let βˆa be the
maximum partial likelihood estimator of βa, for a = 0, 1. We can estimate the cumulative
baseline hazard, Λa(t) =
´ t
0
λa(u)du by the Breslow (1974) estimator
Λˆa(t) =
ˆ t
0
λˆa(u)du, λˆa(u)du =
∑n
j=1 1(Aj = a)dNj(u)∑n
j=1 1(Aj = a)e
βˆTa XjYj(u)
,
and estimate Sa(t | Xi) by Sˆa(t | Xi) = exp
{
−Λˆa(t)eβˆ
T
a Xi
}
. Under standard regularity
conditions, n1/2{Sˆa(t | Xi) − Sa(t | Xi)} converges uniformly to a Gaussian process in
[0, τ ]; see, e.g., Andersen and Gill (1982).
The CAR assumption is not testable and may be questionable for censoring due to
premature dropout. Sensitivity analysis is critical to assess the robustness of study con-
clusions to CAR. Toward that end, we propose sensitive analysis using a wide range of
imputation models including the δ-adjusted models and the control-based models.
Assumption 2 (Delta-adjusted Cox model) The treatment-specific hazard rate of fail-
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ing at time t is λa(t | Xi) given in (4) without premature dropout and is δλa(t | Xi) after
premature dropout (Ri = 2), for a = 0, 1, where δ > 0.
It can be seen that δ quantifies the degree of the departure from the CAR assumption.
If δ = 1, we have CAR. If δ > 1, the hazard increases after dropout, indicating a worsening
of condition after dropout. If δ < 1, the hazard decreases after dropout, indicating an
improvement of condition after dropout. Larger magnitude of δ, larger deviation from
CAR. Without retrieving information for the non-administratively censored subjects, δ
can not be ascertained. Therefore, it is recommended to vary δ in a wide plausible range of
values for sensitivity analysis. To fix ideas, we use the same δ for both treatment groups,
but it is easy to accommodate different δ values depending on the worsening/improvement
condition for different treatment groups. For example, if the control group is a placebo
group, it is reasonable to choose δ to be one for the control subjects who was non-
administratively censored. We illustrate the use of different δ for different treatment
groups in Sections 5 and 6.1.
Control-based models (e.g., Carpenter et al., 2013) are another popular class of sen-
sitivity models. These models are appealing because of their less bias in favor of the
experimental treatment. We focus on jump-to-reference imputation models that assume,
censored subjects follow the same distribution as similar subjects in the control group
after the censored time. These assumptions are plausible for superiority trials when the
subjects do not have access to similar treatments after they were non-administratively
censored.
Assumption 3 (Control-based Cox model) The treatment-specific hazard rate of fail-
ing at time t is λa(t | Xi) given in (4) for a = 0, 1 and is δλ0(t | Xi) after dropout (Ri = 2)
for the treated, where δ > 0.
In fact, both δ-adjusted and control-based sensitivity models entail time-dependent
Cox models. Let the history of the information up to time t beHi(t) = {Xi, Ri, Ni(u), Yi(u) :
u < t}. Because we use Ri = 2 to indicate premature dropout, Assumption 2 describes
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the time-dependent Cox model with the hazard function
λa{t | Hi(t); δ, θ} = λa(t)δ
1(Ri=2 & t>Ui)eβ
T
a Xi, (5)
for a = 0, 1. Similarly, Assumption 3 describes the time-dependent Cox model with the
hazard function
λa{t | Hi(t); δ, θ} =


λ0(t)e
βT
0
Xi if a = 0,
δλ0(t)e
βT
0
Xi if a = 1, Ri = 2, t > Ui
λ1(t)e
βT
1
Xi otherwise.
, (6)
The de facto estimand for treatment policy takes into account the likely attenuation
of the treatment effect after dropout. By (5) and (6), the de facto survival function is
Ssena (t) = E
[
exp
{
−
ˆ t
0
λ{u | Hi(u); δ, θ}du
}]
,
for a = 0, 1. Here we use the superscript “sen” to denote either “δ-adj” or “cb” for the
delta-adjusted or control-based sensitivity model. The de facto treatment effect estimand
becomes ∆senτ = Ψτ{S
sen
1 (t), S
sen
0 (t)}. If the sensitivity parameter δ is not one, ∆
sen
τ differs
from ∆τ in general. By varying δ over a certain range, ∆
sen
τ provides valuable insights on
the impact of CAR, allowing an investigator to assess the extent to which the censoring
assumption alters the treatment effect estimator.
MI requires generating the missing values from the imputation model in Step MI-1.
From (5) or (6), one can derive the conditional survival function Sa{t | Hi(t); δ, θ} for
imputation. Consider the δ-adjusted model for example, if a treated subject i withdrew
from the treatment, the conditional survival at t > Ui is
S1{t | Hi(t); δ, θ} = e
−
´ t
Ui
δλ1(u|Xi)du. (7)
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Unlike the parametric models, sampling from the semiparametric Cox model is diffi-
cult. Following Lipkovich et al. (2016), we introduce a general inverse transform sam-
pling scheme. Suppose we would like to generate T ∗i from (7) for t ≥ Ui. First, gen-
erate a random number ui from Unif[0, pi], where pi = {S1(Ui | Xi)}
δ. Second, solve
{S1(T
∗
i | Xi)}
δ = ui for T
∗
i . Then, we show that given the observed data O1:n,
P (T ∗i ≥ t | O1:n) = P
[
{S1(T
∗
i | Xi)}
δ ≤ {S1(t | Xi)}
δ | O1:n
]
= P
[
ui ≤ {S1(t | Xi)}
δ | O1:n
]
= {S1(t | Xi)}
δ/pi = e
−
´ t
Ui
δλ1(u|Xi)du
is the target imputation model (7).
In practice, we need numerical approximations to obtain T ∗i . Let Ta,max be the largest
observed event time in treatment group a for a = 0, 1. Because Sa(t | Xi) is semipara-
metric, Sˆa(t | Xi) is only available for t ≤ Ta,max. Thus we require τ to be smaller than
T˜max = T0,max ∧ T1,max, and then the imputed value T ∗i can be truncated at T˜max.
To summarize, the MI procedure for δ-adjusted and control-based imputations pro-
ceeds as follows.
Step MI-1-1. Fit a Cox model assuming CAR; denoted by Sa(t | Xi; θˆ).
Step MI-1-2. For administratively censored subject i with (Ai, Ii, Ri) = (a, 0, 1), com-
pute pi = Sa(Ui | Xi; θˆ). Draw a uniform random value ui ∼ Unif[0, pi]. Im-
pute the event time T ∗i as the solution of ui = Sa(t | Xi; θˆ). Numerically, we use
T ∗i = argmaxt∈T {Sa(t | Xi; θˆ) ≥ ui}, where T is the set of realized times to event
or censoring with the largest value being T˜max. This will ensure that the imputed
event time falls between the censoring time and T˜max.
For δ-adjusted imputation model, Step MI-1-3 proceeds as follows.
Step MI-1-3. For non-administratively censored subject i with (Ai, Ii, Ri) = (a, 0, 2),
compute pi = {Sa(Ui | Xi; θˆ)}δ. Draw a uniform random value ui ∼ Unif[0, pi].
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Impute the event time T ∗i as the solution of ui = {Sa(t | Xi; θˆ)}
δ. Numerically, we
use T ∗i = argmaxt∈T [{Sa(t | Xi; θˆ)}
δ ≥ ui].
For control-based imputation model, Step MI-1-3 proceeds as follows.
Step MI-1-3’. For non-administratively censored subject i with (Ai, Ii, Ri) = (0, 0, 2),
draw T ∗i by Step MI-1-3 with a = 0 and δ = 1. For non-administratively censored
subject i with (Ai, Ii, Ri) = (1, 0, 2), draw T
∗
i by Step MI-1-3 with a = 0 and δ, i.e.,
using the corresponding distribution in the control group.
4 Wild Bootstrap Inference based on Martingale Se-
ries
4.1 A novel martingale representation
For variance estimation, the key insight is that the MI estimator is intrinsically created in
a sequential manner: first, the imputation model is fitted based on the observed data; sec-
ond, the missing data are drawn from the imputation model conditioned on the observed
data. This conceptualization leads to a martingale representation of the MI estimator.
We provide heuristic steps below and regulate details to the supplementary material.
We first focus on treatment group a = 1. To unify the notation, let T
∗(j)
i denote
the jth imputed value for subject i if subject i was censored and the observed Ti if we
observe subject i’s event time. By the imputation mechanism, T
∗(j)
i follows the conditional
survival distribution S1{t | Hi(t); θˆ} for t ≥ Ui, where θ = {λa(·), βa : a = 0, 1}. Then,
for t ∈ [0, τ ], it is insightful to express
n1/2
{
Sˆ1,mi(t)− S
sen
1 (t)
}
=
n1/2
mn1
m∑
j=1
n∑
i=1
Ai{1(T
∗(j)
i ≥ t)− S
sen
1 (t)}
=
n1/2
mn1
m∑
j=1
n∑
i=1
Ai{1− Yi(t)}
[
1(T
∗(j)
i ≥ t)− S1{t | Hi(t); θˆ}
]
(8)
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+
n1/2
n1
n∑
i=1
Ai
[
S1{t | Hi(t); θˆ} − S
sen
1 (t)
]
. (9)
Here, we use the total sample size n for scaling; we will use the same scaling for the
estimators for the control group and the treatment effect.
We analyze the two terms in (8) and (9), separately. First, because the imputations
are independent given the observed data, it follows that the individual terms in (8) are
independent mean-zero terms conditional on the observed data. Second, because the term
in (9) depends on θˆ, by exploiting the counting process theory, we express
n1/2
n1
n∑
i=1
Ai
[
S1{t | Hi(t); θˆ} − S
sen
1 (t)
]
=
n1/2
n1
n∑
i=1
Ai [Yi(t) + {1− Yi(t)}(1− Ii)S1{t | Hi(t); θ} − S
sen
1 (t)] (10)
+
n1/2
n1
n∑
i=1
Aiφ11,i(t) +
n1/2
n1
n∑
i=1
(1− Ai)φ10,i(t) + op(1), (11)
where the exact expressions of φ11,i(t) and φ10,i(t) are given in Section S2. Importantly,
φ11,i(t) reflects the estimation of {λ1(·), β1}, φ10,i(t) reflects the estimation of {λ0(·), β0},
and E{φ11,i(t)} = E{φ10,i(t)} = 0. Note that in the sensitivity analysis using the δ-
adjusted models, the imputation for the treated group uses the information only from the
treated group, so φ11,i(t) 6= 0 and φ10,i(t) = 0 for all i; while in the sensitivity analysis
using the control-based models, the imputation for the treated group uses information
from both treatment groups, so φ11,i(t) 6= 0 and φ10,i(t) 6= 0 for all i. Also, by definition,
the expectation of the term in (10) is zero. Together, n1/2{Sˆ1,mi(t)−Ssen1 (t)} decomposes
into the summation of three terms (8), (10), and (11) with (conditional) mean zero, and
converges to a Gaussian process in [0, τ ].
Similarly, we have
n1/2
{
Sˆ0,mi(t)− S
sen
0 (t)
}
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=
n1/2
mn0
m∑
j=1
n∑
i=1
(1− Ai){1− Yi(t)}
[
1(T
∗(j)
i ≥ t)− S0{t | Hi(t); θˆ}
]
(12)
+
n1/2
n0
n∑
i=1
(1− Ai) [Yi(t) + {1− Yi(t)}(1− Ii)S0{t | Hi(t); θ} − S
sen
0 (t)] (13)
+
n1/2
n0
n∑
i=1
(1− Ai)φ0,i(t) + op(1), (14)
where the exact expression of φ0,i(t) is given in Section S2, reflecting the estimation of
{λ0(·), β0}. In our context, the imputation for the control group uses the information
only from the control group. By the imputation and estimation procedures, (12)–(14)
have (conditional) mean zero.
We now leverage the unified linear characterization (1) to express the MI estimator
for various treatment effect estimands. Combining (1) and the above decompositions of
Sˆ1,mi(t) and Sˆ0,mi(t), we derive
n1/2(∆ˆτ,mi −∆τ ) = n
1/2
[
Ψτ{Sˆ1,mi(t), Sˆ0,mi(t)} −∆τ
]
=
(1+m)n∑
k=1
ξn,k + op(1), (15)
where
ξn,k =
n1/2
n1
ˆ τ
0
ψ1(t)Ai
[
φ11,i(t) + Yi(t) + {1− Yi(t)}(1− Ii)S1{t | Hi(t); θ} − S
sen
1 (t)] dt,
for k = i (1 ≤ i ≤ n1),
ξn,k =
n1/2
mn1
ˆ τ
0
ψ1(t)Ai{1− Yi(t)}[1(T
∗(j)
i ≥ t)− S1{t | Hi(t); θˆ}]dt,
for k = n1 + (i− 1)m+ j (1 ≤ i ≤ n1, 1 ≤ j ≤ m),
ξn,k =
n1/2
n0
ˆ τ
0
ψ0(t)(1−Ai)
[
φ10,i(t) + φ0,i(t) + Yi(t) (16)
+ {1− Yi(t)}(1− Ii)S0{t | Hi(t); θ} − S
sen
0 (t)] dt,
for k = (1 +m)n1 + i, (n1 + 1 ≤ i ≤ n),
ξn,k =
n1/2
mn0
ˆ τ
0
ψ0(t)(1− Ai){1− Yi(t)}[1(T
∗(j)
i ≥ t) − S0{t | Hi(t); θˆ}]dt,
for k = (1 +m)n1 + n0 + (i− 1)m+ j (n1 + 1 ≤ i ≤ n, 1 ≤ j ≤ m).
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To gain intuitions, based on the decomposition in (15), the first n1 terms of ξn,k con-
tribute to the variability of Sˆ1,mi because of the unknown parameters, and the next mn1
terms of ξn1,k contribute to the variability of Sˆ1,mi because of the imputations given the
estimated parameter values, reflecting the sequential MI procedure. Other terms have
similar explanations.
Consider the σ-fields
Fn,k =


σ (O1, . . . , Ok) , for k = i (1 ≤ i ≤ n1),
σ
(
O1, . . . , On1, T
∗(1)
1 , . . . , T
∗(j)
i
)
, for k = n1 + (i− 1)m+ j
(1 ≤ i ≤ n1, 1 ≤ j ≤ m),
σ
(
O1, . . . , On1, T
∗(1)
1 , . . . , T
∗(m)
n1 , for k = (1 +m)n1 + i
On1+1, . . . , Ok
)
, (n1 + 1 ≤ i ≤ n),
σ
(
O1, . . . , On1, T
∗(1)
1 , . . . , T
∗(m)
n1 , for k = (1 +m)n1 + n0 + (i− 1)m+ j
On1+1, . . . , On, T
∗(1)
n1+1, . . . , T
∗(j)
i
)
, (n1 + 1 ≤ i ≤ n, 1 ≤ j ≤ m).
The key is that
{
k∑
i=1
ξn,i,Fn,k, 1 ≤ k ≤ (1 +m)n
}
is a martingale for each n ≥ 1. (17)
This result is mainly due to our earlier decompositions of Sˆ1,mi and Sˆ0,mi into (conditional)
mean zero terms. We focus on the ξn,k terms for treatment group a = 1, because the
discussion for the ξn,k terms for treatment group a = 0 is similar. Obviously, E(ξn,1) = 0
and E(ξn,k | O1:k−1) = E(ξn,k) = 0 for 1 < k ≤ n1. Under the regularity conditions,
E(ξn,k | Fn,k−1) = 0 for k = n1 + (i − 1)m + j, where i = 1, . . . , n1, and j = 1, . . . , m.
Therefore, (17) follows.
The martingale representation allows us to characterize the asymptotic distribution of
∆ˆτ,mi with the proof presented in Section S2.
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Theorem 1 Under Assumptions 1, 2/3, and S1, n1/2(∆ˆτ,mi − ∆τ ) → N (0, V
sen
τ,mi), as
n→∞, where V senτ,mi is a finite variance given in (S20).
4.2 Wild bootstrap for the MI estimator
The martingale representation invokes the wild or weighted bootstrap procedure (Wu,
1986; Liu, 1988) that provides valid variance estimation and inference of the linear statistic
for martingale difference arrays. Pauly (2011) proved the validity of the wild bootstrap re-
sampling under the conditions of a general central limit theorem (CLT). Guan and Yang
(2019) applied the wild bootstrap for a martingale series in the context of causal inference
with observational studies.
Based on the martingale representation (15), we propose the wild bootstrap procedure
to estimate the variance of ∆ˆτ,mi. The martingale representation relies on unknown quan-
tities, requiring approximations. We then estimate (i) Ssena (t) by Sˆa,mi, (ii) φ11,i(t), φ10,i(t),
and φ0,i(t) by φˆ11,i(t), φˆ10,i(t), and φˆ0,i(t), and (iii) Sa{t | Hi(t); θ} by Sa{t | Hi(t); θˆ}, for
a = 0, 1.
Based on the above approximations, the wild bootstrap inference proceeds as follows.
Step WB-1. Sample uk, for k = 1, . . . , (1 +m)n, that satisfy E(uk | O1:n) = 0, E(u2k |
O1:n) = 1 and E(u
4
k | O1:n) <∞.
Step WB-2. Compute the bootstrap replicate as W ∗L = n
−1/2
∑(1+m)n
k=1 ξˆn,kuk, where
ξˆn,k is the empirical version of ξn,k by replacing the unknown quantities with their
estimators and the integral by the numerical integration.
Step WB-3. Repeat Steps 1 and 2 B times, and estimate the variance of ∆ˆτ,mi by the
sample variance of these copies of W ∗L.
Remark 1 There are many choices for generating µk, such as the the standard normal
distribution, Mammen’s Mammen (1993) two point distribution, a simpler distribution
with probability 0.5 of being 1 and probability 0.5 of being −1, or the nonparametric boot-
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strap weights. The wild bootstrap procedure is not sensitive to the choice of the sampling
distribution of µk. We adopt the standard normal distribution in the simulation study.
Remark 2 It is worth discussing the connection between the martingale representation
(15) and existing results in the survival literature. Under CCAR, Zhao et al. (2016) de-
rived an asymptotic linearization for the RMST estimator and proposed the perturbation-
resampling variance estimation by adding independent noises to the linearized terms. In
this simpler case, by setting the sensitivity parameter δ to be 1 and omitting the imputation
step, our martingale representation with the first n1 terms reduces to their linearization.
The slight difference lies in the distribution for generating the resampling weights. In
the wild bootstrap, the resampling weight distribution has mean 1; while in the pertur-
bation, the resampling weight distribution has mean 0. This difference would not affect
the variance estimation. Our framework allows for CAR and sensitivity analysis using
δ-adjustment/control-based models, taking into account variability from both parameter
estimation and imputation.
Theorem 2 shows the asymptotic validity of the above bootstrap inference method.
Theorem 2 Under Assumptions 1, 2/3, and S1, we have
sup
r
∣∣∣P (n1/2W ∗L ≤ r | O1:n)− P{n1/2(∆ˆτ,mi −∆senτ ) ≤ r}∣∣∣→ 0,
in probability, as n→∞.
We provide the proof of Theorem 2 in the supplementary material, which draws on
the martingale central limit theory (Hall and Heyde, 1980) and the asymptotic property
of weighted sampling of martingale difference arrays (Pauly, 2011). Theorem 2 indicates
that the distribution of the wild bootstrap statistic consistently estimates the distribution
of the MI estimator.
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5 Simulation
We conduct simulation studies to evaluate the finite sample performance of the pro-
posed SMIM framework. For illustration, we focus on the δ-adjusted model for sensitivity
analysis and the RMST as the treatment effect estimand. For both the treatment and
control groups, each with sample size n ∈ {500, 1000}, the confounder is generated by
Xi ∼ N (0, 1). In the treatment group, T follows the Cox model with the hazard rate
λ1(t | Xi) = λ1(t) exp(β1Xi), where λ1(t) = 0.35 and β1 = 0.75. We consider censoring
due to the end of the study and premature dropout. We generate the censoring time to
dropout, Ci, according to a Cox model with the hazard rate λC(t | X) = λC(t) exp(βCXi),
where λC(t) = 0.15 and βC = 0.75. The maximum follow up time is L = 3.25. The ob-
served time is Ui = Ti ∧ Ci ∧ L. If Ui = Ti, the event indicator is Ii = 1; if Ui = L,
then Ii = 0 and the censoring type is Ri = 1; if Ui = Ci, then Ii = 0 and the censoring
type is Ri = 2. Under the data generating mechanism, the average percentages of Ii = 1,
Ri = 1, and Ri = 2 are 53%, 25%, and 22%, respectively. For the dropout subjects with
Ri = 2, the hazard rate for event after censoring is δλ1(t) exp(β1X). In the control group,
Ti follows the hazard rate λ0(t | X) = λ0(t) exp(β0X), where λ0(t) = 0.40 and β0 = 0.75.
The censoring time Ci follows the same model as in the treatment group. Moreover, we
assume that the hazard rate for event after censoring remains the same, which corresponds
to the case when the control treatment is a placebo or the standard of care. The true
RMST estimands under the δ-adjusted model are µδ-adj1,τ , µ0,τ , and ∆
δ-adj
τ = µ
δ-adj
1,τ − µ0,τ
with τ = 3. We assess the proposed method to implement the sensitivity analysis for the
treatment group when the true parameter δ is 1.5, while the analysis parameter δ varies
in a pre-specified set {0.5, 1, 1.5, 2, 2.5}.
We use MI for imputing the censored event times following Steps MI-1-1, MI-1-2
and MI-1-3 in Section 3 with imputation size m ∈ {3, 10}. We compare the standard
MI inference and the proposed wild bootstrap inference. For the standard MI infer-
ence, the 100(1− α)% confidence intervals are calculated as (∆ˆτ,mi − z1−α/2Vˆ
1/2
mi , ∆ˆτ,mi +
z1−α/2Vˆ
1/2
mi ), where z1−α/2 is the (1 − α/2)th quantile of the standard normal distri-
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bution. For the proposed wild bootstrap procedure, we sample the weights µk from
the standard normal distribution, and calculate the variance estimate VˆWB based on
100 replications. The corresponding 100(1 − α)% confidence intervals are calculated as
(∆ˆτ,mi−z1−α/2Vˆ
1/2
WB , ∆ˆτ,mi+z1−α/2Vˆ
1/2
WB). We assess the performance in terms of the relative
bias of the variance estimator and the coverage rate of confidence intervals. The relative
bias of the variance estimators are calculated as {E(Vˆ 1/2mi )− V(∆ˆ
1/2
τ,mi)}/V(∆ˆ
1/2
τ,mi) × 100%
and {E(Vˆ 1/2WB)−V(∆ˆ
1/2
τ,mi)}/V(∆ˆ
1/2
τ,mi)× 100%. The coverage rate of the 100(1−α)% confi-
dence intervals is estimated by the percentage of the Monte Carlo samples for which the
confidence intervals contain the true value.
Table 1 presents the simulation results for the sensitivity analysis of ∆δ-adjτ based
on 1000 Monte Carlo samples. When the imputation model is correctly specified with
δ = 1.5, the MI point estimator ∆ˆτ,mi is unbiased of the true estimand ∆
δ-adj
τ . When the
analysis sensitivity parameter is lower (higher) than the true parameter δ = 1.5, the MI
point estimator produces higher (lower) RMST for the treatment group, see Figure S1,
and therefore ∆ˆτ,mi is biased upward (downward). When the true sensitivity parameter
is correctly specified, Rubin’s combining rule overestimates the true standard deviation
with the relative bias ranging from 11.3% to 14.9%; consequently, the coverage rates are
larger than the nominal level 95%. In contrast, our proposed wild bootstrap procedure is
unbiased; as a result, the coverage rates of the confidence intervals are close to the nominal
level. Moreover, the proposed method is not sensitive to the number of imputations m.
The same discussions apply to the results for the treatment-specific RMSTs as presented
in Section S4. In particular, for the control RMST, CAR is assumed, therefore, the
proposed SMIM framework can also be adopted beyond sensitivity analysis.
6 Applications
We apply the proposed semiparametric δ-adjusted Cox model to a HIV clinical trial and
a cardiovascular clinical trial.
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Table 1: Simulation results for the true estimand ∆δ-adjτ = 0.054 with the true sensitivity
parameter δ = 1.5: point estimate, true standard deviation, relative bias of the standard
error estimator, coverage of interval estimate using Rubin’s method and the proposed
wild bootstrap method
Point est True sd
Standard error Relative Bias Coverage (%)
(×102) (%) for 95% CI
n δ m (×102) (×102) Rubin WB Rubin WB Rubin WB
0.5
5 15.9 6.50 7.50 6.78 15.24 4.18 74.4 66.3
10 16.0 6.54 7.43 6.80 13.68 4.11 73.3 67.8
1
5 9.5 6.50 7.47 6.74 15.06 3.73 95.1 90.8
10 9.6 6.53 7.41 6.76 13.46 3.58 93.8 91.6
500
1.5
5 5.2 6.47 7.44 6.74 14.91 4.11 97.6 96.1
10 5.4 6.51 7.38 6.76 13.36 3.93 97.5 95.6
2
5 2.2 6.45 7.41 6.75 14.81 4.63 96.0 93.6
10 2.3 6.48 7.35 6.77 13.39 4.53 95.4 94.0
2.5
5 -0.1 6.43 7.38 6.76 14.71 5.11 92.0 88.5
10 0.1 6.45 7.32 6.78 13.44 5.12 93.0 89.3
0.5
5 15.9 4.61 5.30 4.80 15.11 4.17 51.0 42.8
10 16.0 4.69 5.26 4.79 12.09 2.17 49.4 42.3
1
5 9.5 4.58 5.29 4.77 15.29 4.04 91.2 87.3
10 9.6 4.69 5.24 4.76 11.78 1.64 90.0 85.6
1000
1.5
5 5.2 4.58 5.26 4.77 14.94 4.22 96.8 95.3
10 5.4 4.69 5.22 4.77 11.34 1.72 97.0 95.1
2
5 2.1 4.57 5.24 4.78 14.68 4.59 92.8 90.0
10 2.2 4.68 5.20 4.77 11.08 2.07 92.8 90.4
2.5
5 -0.1 4.56 5.22 4.79 14.50 4.99 84.4 80.1
10 -0.0 4.67 5.18 4.78 10.89 2.44 84.1 80.0
6.1 HIV clinical trial
The randomized double-blinded ACTG175 trial was conducted to compare the treatment
effect of a single nucleoside and two nucleosides in adults with HIV (Hammer et al., 1996).
The dataset is available in the R package speff2trial. The event of interest was the
progression of the disease defined as the first occurrence of more than 50 percent decline
in the CD4 cell count or death. For illustration purposes, we compare the treatment effect
between Zidovudine monotherapy and Zidovudine plus Didanosine combination therapy
in a subgroup of participants who never took any type of antiretroviral therapy before
randomization. In this subgroup, there were 197 subjects in the monotherapy group and
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185 subjects in the combination therapy group. While re-analyzing the data, we apply
the proposed δ-adjusted Cox model with δ = 1, i.e., CAR, as the primary approach for
estimating the RMSTs. The truncation time point for the RMST is 24 months because
the ACTG175 study required at least 24 months follow-up for subjects. The estimated
RMST with 95% confidence interval is 22.1 (21.5, 22.6) months in the monotherapy group
v.s. 23.0 (22.5, 23.5) in the combination therapy. The estimated between-group RMST
difference with 95% confidence interval is 0.93 (0.20, 1.6). P-value is 0.013 that indicates
a statistically significant improvement of the combination therapy compared with the
monotherapy.
We conduct the sensitivity analysis based on the δ-adjusted model to evaluate the
impact of the CAR assumption in the primary analysis. In the sensitivity analysis, we
consider subjects censored before 24 months as censored for non-administrative reasons
and subjects censored after 24 months as censored for administrative reasons. The δ-
adjustment is applied to subjects who were non-administratively censored in the treat-
ment group. We assume CAR for subjects who were administratively censored in the
combination therapy group or censored in the monotherapy group, i.e., δ = 1. For each
treatment group, the δ-adjusted Cox models include age, baseline CD4 T-cell count, and
symptomatic indicator terms with different values of δ. We estimate the standard errors
by Rubin’s combining rule and the proposed wild bootstrap method.
Table 2 summarizes the results. The estimated within- and between-group standard
errors from the wild bootstrap are smaller than that from Rubin’s combining rule for all
δ’s. This is coherent with the findings in the simulation study. From the p-value of each
δ, the estimated tipping point of the sensitivity analysis is larger than 5 by using wild
bootstrap and between 3 and 4 by using Rubin’s rule. The results from the proposed
wild bootstrap method demonstrate a stronger evidence for the robustness of the primary
analysis compared with the conservative Rubin’s rule. From the sensitivity results based
on the wild bootstrap, to eliminate the statistical significance of the treatment effect, the
hazard of those subjects who were non-administratively censored should be more than 5
times higher than subjects with the observed event times in the same group. Therefore,
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Table 2: Analysis of the ACTG175 Trial Data
Zidovudine Zidovudine plus
(n = 197) Didanosine (n = 185) Difference
δ† RMST SE RMST SE RMST (95% CI) SE P-Value
Primary and Sensitivity Analysis with Wild Bootstrap
1 22.10 0.28 23.03 0.25 0.93 (0.20, 1.67) 0.37 0.013
2 22.10 0.28 22.97 0.25 0.88 (0.14, 1.61) 0.37 0.019
3 22.10 0.28 22.93 0.25 0.83 (0.10, 1.57) 0.37 0.026
4 22.10 0.28 22.89 0.25 0.79 (0.06, 1.52) 0.37 0.034
5 22.10 0.28 22.85 0.25 0.75 (0.02, 1.49) 0.38 0.045
Primary and Sensitivity Analysis with Rubin’s Combining Rule
1 22.10 0.32 23.03 0.24 0.93 (0.14, 1.73) 0.40 0.021
2 22.10 0.32 22.97 0.25 0.88 ( 0.07, 1.68) 0.41 0.033
3 22.10 0.32 22.93 0.26 0.83 ( 0.02, 1.64) 0.41 0.044
4 22.10 0.32 22.89 0.26 0.79 (-0.02, 1.61) 0.42 0.057
5 22.10 0.32 22.85 0.27 0.75 ( -0.07, 1.58) 0.42 0.072
†The value of δ applied to subjects who were non-administrative censored in the
Zidovudine plus Didanosine group.
the findings from the primary analysis is robust to the censoring assumption.
6.2 Cardiovascular clinical trial
The randomized double-blinded IMPROVE-IT study was conducted to evaluate the clini-
cal benefit of Ezetimibe/Simvastatin (ez/simva) Combination compared with Simvastatin
(simva) in patients with high-risk acute coronary syndrome (ACS) (Cannon et al., 2015).
One of the events of interest is the composite endpoint of time to coronary heart disease
death, non-fatal myocardial infarction, and urgent coronary revascularization with either
percutaneous coronary intervention or coronary artery bypass grafting occurring at least
30 days after randomization. A total of 18, 144 subjects were randomized into the study,
the event of interest occurred in 1, 322 of 9, 067 (15%) subjects in the ez/simva group and
1, 448 of 9, 077 (16%) subjects in the simva only group. In our analysis, the RMST is
defined as the average event-free survival time up to 84 months, the time point shown in
the report for the IMPROVE-IT study (Cannon et al., 2015).
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We apply the proposed δ-adjusted Cox model with δ = 1, i.e., CAR, as the primary
approach for estimating the RMSTs. For each treatment group, the δ-adjusted Cox
models include three baseline indicators of early use of eptifibatide , chronic prescription
lipid-lowering experience, and high-risk ACS diagnosis. In the sensitivity analysis, we
evaluate the impact of potential informative censoring for subjects that did not complete
the final visit on or after May 1st, 2014 without event of interest. There were 1, 594
(18%) subjects in the ez/simva group and 1, 576 (17%) subjects in the simva only group
that were potentially informative censored. The δ-adjustment is applied to these subjects.
CAR (δ = 1) is assumed for subjects who were administratively censored (i.e., subjects
completed final visit on or after May 1st, 2014 without the event of interest). Different
values of δ are applied to evaluate the impact of the degree of the violation of the CAR
assumption. The imputation model and the truncation time point are the same as in the
primary analysis.
Table 3 summarizes the results. In the primary analysis (δ = 1), the estimated RMST
with 95% CI using the wild bootstrap is 75.1 (CI: 74.7, 75.6) in the ez/simva group v.s.
74.4 (CI: 73.9, 74.9) months in the simva group. The estimated between-group RMST
difference is 0.75 (CI: 0.08, 1.43). P-value is 0.029 that indicates the statistical signifi-
cance of the treatment effect for the ez/simva group compared with the simva group. The
analysis results using Rubin’s rule are similar to that using the wild bootstrap. In the
sensitivity analysis using the same δ, the estimated standard error from the wild boot-
strap is smaller compared with that from Rubin’s rule. This is coherent with the findings
in the simulation studies. From the p-value of each δ, the estimated tipping point of the
sensitivity analysis is larger than 2.5 by using the wild bootstrap and between 1.5 and 2.0
by using Rubin’s rule. The results from the proposed wild bootstrap method demonstrate
a stronger evidence for the robustness of the primary analysis compared with the conser-
vative Rubin’s rule. From the sensitivity results based on the wild bootstrap, to eliminate
the statistical significance of the treatment effect, the hazard of those subjects who were
non-administratively censored should be more than 2.5 times higher than subjects with
the observed event times in the same group. Therefore, the findings from the primary
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Table 3: Analysis of the IMPROVE-IT study
EZ/Simva Simva Didanosine
(n = 9067) (n = 9077) Difference
δ† RMST SE RMST SE RMST (95% CI) SE P-Value
Primary and Sensitivity Analysis with Wild Bootstrap
1.0 75.14 0.23 74.39 0.26 0.75 ( 0.08, 1.43) 0.35 0.029
1.5 74.84 0.23 74.11 0.26 0.73 ( 0.06, 1.41) 0.35 0.034
2.0 74.56 0.23 73.84 0.26 0.71 ( 0.03, 1.39) 0.35 0.039
2.5 74.29 0.23 73.59 0.26 0.70 ( 0.02, 1.39) 0.35 0.043
3.0 74.04 0.24 73.34 0.27 0.70 (-0.00, 1.40) 0.36 0.051
Primary and Sensitivity Analysis with Rubin’s Combining Rule
1.0 75.14 0.24 74.39 0.25 0.75 (0.07, 1.43) 0.35 0.030
1.5 74.84 0.25 74.11 0.25 0.73 ( 0.03, 1.43) 0.36 0.040
2.0 74.56 0.26 73.84 0.26 0.71 (-0.01, 1.43) 0.37 0.053
2.5 74.29 0.27 73.59 0.27 0.70 (-0.03, 1.44) 0.38 0.061
3.0 74.04 0.27 73.34 0.27 0.70 (-0.05, 1.45) 0.38 0.069
†The value of δ applied to informative censored subjects.
analysis is reassuring.
7 Concluding Remarks
In this article, we provide a general framework for survival sensitivity analysis based on
semiparametric δ-adjusted/control-based Cox models to assess the impact of CAR. The
δ-adjusted/control-based models are flexible enough to accommodate different censoring
mechanisms by changing the sensitivity parameter. MI facilitates the use of simple full-
sample estimator; however, the standard Rubin’s combining rule may not be valid in the
sensitivity analysis framework. We reformulate the MI estimator as a martingale series
based on the sequential construction of the MI estimator and propose the wild bootstrap
inference based on resampling the martingale series. The new bootstrap inference has a
theoretical guarantee for consistency and computational advantages.
In contrast to most existing sensitivity analysis methods using parametric models, the
δ-adjusted Cox model is semiparametric. We present an analytical form of the conditional
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subject-specific survival distribution which enables drawing the censored event times di-
rectly from an estimated model. This sampling strategy is the so-called “improper” MI.
We note that the proposed wild bootstrap inference applies similarly to “proper” MI,
where the censored event times can be drawn from a Bayesian posterior predictive distri-
bution.
Recently, Cro et al. (2019) suggested that control-based imputation permits “informa-
tion anchored” analysis in the sense that the information ratio between the analysis with
missing data and the analysis with “complete” data is similar for the primary analysis and
the sensitivity analysis. For the longitudinal continuous data, they showed that standard
errors for the primary analysis and the sensitivity analysis are approximately the same,
and Rubin’s combining rule works for information-anchored analysis when the proportion
of missing data is not large. However, more general results extending to the survival
data are challenging. Here, based on our simulation result, Rubin’s combining rule is
conservative for the RMSTs and the treatment effect under the δ-adjusted sensitivity
analysis.
We present the sensitivity analysis framework in the clinical trial setting, where due
to treatment randomization at baseline, the covariate distribution is balanced between
treatment groups. In an observational study, treatment comparisons may be difficult to
make because of confounding. Chen and Tsiatis (2001) proposed regression-based analysis
and Zhang and Schaubel (2012) proposed weighting-based analysis for the RMST under
CAR in observational studies. In the future, we will extend the proposed SMIM framework
to assess the robustness of study conclusions against CAR in observational studies.We
will also consider other scenarios with additional missing covariates, repeated measures
in longitudinal data, or recurrent event data (Akacha and Ogundimu, 2016; Gao et al.,
2017).
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Supplementary Materials
The online supplementary material contains technical assumptions, proofs, and additional
simulation results, and the R code that implements the proposed method is available.
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Supplementary Material for “SMIM: a unified
framework of survival sensitivity analysis using
multiple imputation and martingale”
Section S1 provides the preliminary for the proofs. Sections S2 and S3 provide the
proofs of Theorem 1 and Theorem 2. Section S4 presents the additional simulation results.
S1 Preliminary
We adopt the counting process theory of Andersen and Gill (1982) in our theoretical
framework. We state the existing results which will be used in our proof throughout.
To simplify the exposition, we introduce additional notation. We use
p
→ and
d
→ to
represent “converge in probability as n→∞” and “converge in distribution as n→∞”,
respectively. Also, let n1/n → p1 ∈ (0, 1) and n0/n → p0 ∈ (0, 1), as n → ∞. We do
not state this condition formally as an assumption because it holds trivially for most of
clinical trials where the two treatment groups are relatively balanced in their sample sizes.
Let X⊗li denote 1 for l = 0, Xi for l = 1, and XiX
T
i for l = 2. Define
U (l)a (βa, t) =
1
na
n∑
i=1
1(Ai = a)X
⊗l
i e
βTa XiYi(t), u
(l)
a (βa, t) = E
{
X⊗leβ
T
a XY (t)
}
,
where u
(l)
a (βa, t) is the expectation of U
(l)
a (βa, t), for l = 0, 1, 2. Moreover, define
Ea(βa, t) =
U
(1)
a (βa, t)
U
(0)
a (βa, t)
, ea(βa, t) =
u
(1)
a (βa, t)
u
(0)
a (βa, t)
.
1
The maximum partial likelihood estimator βˆa solves
Sa,n(βa) =
1
na
n∑
i=1
1(Ai = a)
ˆ τ
0
{
Xi −
U
(1)
1 (βa, u)
U
(0)
1 (βa, u)
}
dNi(u) = 0.
We state the standard asymptotic results for βˆa and λˆa(·) requiring certain regularity
conditions. To avoid too many technical distractions, we omit the exact conditions in
Assumption S1 for the consistency and uniform convergency of the estimators of Cox’s
models.
Assumption S1 Conditions A–D in Andersen and Gill (1982) hold for treatment group
a = 0, 1.
Following Andersen and Gill (1982), we have
n1/2a (βˆa − βa) = Γ
−1
a
1
n
1/2
a
n∑
i=1
1(Ai = a)Ha,i + op(1), (S1)
where Γa = E{−∂Sa,n(βa)/∂βTa } is the Fisher information matrix of βa, Ha,i =
´ L
0
{Xi −
ea(βa, u)}1(Ai = a)dMa,i(u), and
dMa,i(t) = dNi(u)− e
βTa XiYi(u)λa,0(u)du. (S2)
Moreover, n1/2{Sa(t | Xi; θˆ) − Sa(t | Xi)} converges uniformly to a Gaussian process in
[0, L] for all Xi.
S2 Proof of Theorem 1
We first derive the martingale representation of the MI estimator under δ-adjusted Cox
models and control-based Cox models, separately. Then, we apply the martingale CLT
to derive the asymptotic distribution of the MI estimator.
2
S2.1 Delta-adjusted Cox models
A key step is to separate the imputation step and the estimation step. We start with
treatment group a = 1. For the imputations, it is important to recognize that T
∗(j)
i follows
a time-dependent Cox model with the conditional survival function S1{t | Hi(t); θˆ} for
t > Ui, where
S1{t | Hi(t); θ} =


exp
{
−
´ t
Ui
λ1(u)e
βT
1
Xidu
}
, if Ai = 1, Ri = 1,
exp
{
−δ
´ t
Ui
λ0(u)e
βT
0
Xidu
}
, if Ai = 1, Ri = 2.
We express the MI estimator of Sδ-adj1 (t) as
n1/2
{
Sˆ1,mi(t)− S
δ-adj
1 (t)
}
=
n1/2
mn1
m∑
j=1
n∑
i=1
Ai{1(T
∗(j)
i ≥ t)− S
δ-adj
1 (t)}
=
n1/2
mn1
m∑
j=1
n∑
i=1
Ai[1(T
∗(j)
i ≥ t)− S1{t | Hi(t); θˆ}] +
n1/2
n1
n∑
i=1
Ai[S1{t | Hi(t); θˆ} − S
δ-adj
1 (t)]
=
n1/2
mn1
m∑
j=1
n∑
i=1
Ai{1− Yi(t)}[1(T
∗(j)
i ≥ t)− S1{t | Hi(t); θˆ}] (S3)
+
n1/2
n1
n∑
i=1
[
AiYi(t) + Ai{1− Yi(t)}(1− Ii)S1{t | Hi(t); θˆ} − S
δ-adj
1 (t)
]
+ op(1), (S4)
where (S3) follows because 1(T
∗(j)
i ≥ t) − S1{t | Hi(t); θˆ} = 0 for subject i with {Ai =
1,Yi(t) = 1}, and (S4) follows because Ai{1− Yi(t)}IiS1{t | Hi(t); θˆ} = 0.
By the counting process theory, we can express the term n
−1/2
1
∑n
i=1Ai{1−Yi(t)}(1−
Ii)S1{t | Hi(t); θˆ} in (S4) further as
1
n
1/2
1
n∑
i=1
Ai{1− Yi(t)}(1− Ii)S1{t | Hi(t); θˆ}
=
1
n
1/2
1
n∑
i=1
Ai{1− Yi(t)}(1− Ii) exp
{
−
ˆ t
Ui
λˆ1(u)δ
1(Ri=2)eβˆ
T
1
Xidu
}
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=
1
n
1/2
1
n∑
i=1
Ai{1− Yi(t)}(1− Ii)S1{t | Hi(t); θ}
+
1
n
1/2
1
n∑
i=1
Ai{1− Yi(t)}(1− Ii)S1{t | Hi(t); θ}
[
−
ˆ t
Ui
δ1(Ri=2)eβ
T
1
Xi
{
λˆ1(u)− λ1(u)
}
du
]
(S5)
+
[
1
n1
n∑
i=1
Ai{1− Yi(t)}(1− Ii)S1{t | Hi(t); θ}
{
−
ˆ t
Ui
λ1(u)δ
1(Ri=2)eβ
T
1
XiXidu
}]
(S6)
×n
1/2
1
(
βˆ1 − β1
)
. (S7)
For (S5), we further express the key term as
ˆ t
Ui
δ1(Ri=2)eβ
T
1
Xi
{
λˆ1(u)− λ1(u)
}
du
=
ˆ t
Ui
δ1(Ri=2)eβ
T
1
Xi
{
n−11
∑n
j=1AjdNj(u)
U
(0)
1 (βˆ1, u)
−
n−11
∑n
j=1AjdNj(u)
U
(0)
1 (β1, u)
}
+
ˆ t
Ui
δ1(Ri=2)eβ
T
1
Xi
{
n−11
∑n
j=1AjdNj(u)
U
(0)
1 (β1, u)
− λ1(u)du
}
= −

ˆ t
Ci
δ1(Ri=2)eβ
T
1
Xi
U
(1)
1 (β1, u){
U
(0)
1 (β1, u)
}2
{
n−11
n∑
j=1
dNj(u)
}
T (
βˆ1 − β1
)
+
ˆ t
Ui
δ1(Ri=2)eβ
T
1
Xi
n−11
∑n
j=1AjdM1,j(u)
U
(0)
1 (β1, u)
+ op(1)
= −
{ˆ t
Ui
δ1(Ri=2)eβ
T
1
Xie1(β1, u)λ1(u)du
}T (
βˆ1 − β1
)
+
ˆ t
Ui
δ1(Ri=2)eβ
T
1
Xi
n−11
∑n
j=1AjdM1,j(u)
U
(0)
1 (β1, u)
+ op(1), (S8)
where dM1,j(u) is defined in (S2). Denote
ga,0(t) = E
[
1(Ai = a){1 − Yi(t)}(1 − Ii)Sa{t | Hi(t); θ}δ
1(Ri=2)eβ
T
a Xi
]
,
ga,1(t) = E
[
1(Ai = a){1 − Yi(t)}(1 − Ii)Sa{t | Hi(t); θ}
{ˆ t
Ui
δ1(Ri=2)eβ
T
a XiXiλa(u)du
}]
,
ga,2(t) = E
[
1(Ai = a){1 − Yi(t)}(1 − Ii)Sa{t | Hi(t); θ}
{ˆ t
Ui
δ1(Ri=2)eβ
T
a Xiea(βa, u)λa(u)du
}]
,
for a = 0, 1.
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Plugging (S8) in (S5) becomes
1
n
1/2
1
n1∑
i=1
Ai{1− Yi(t)}(1− Ii)S1{t | Hi(t); θˆ}
=
1
n
1/2
1
n1∑
i=1
Ai{1− Yi(t)}(1− Ii)S1{t | Hi(t); θ}
+ {g1,2(t)− g1,1(t)}
T n
1/2
1
(
βˆ1 − β1
)
− n−1/21
n∑
j=1
ˆ t
Uj
g1,0(u)
s0(β1, u)
AjdM1,j(u) + op(1)
=
1
n
1/2
1
n1∑
i=1
Ai{1− Yi(t)}(1− Ii)S1{t | Hi(t); θ}
+
1
n
1/2
1
n1∑
i=1
[
{g1,2(t)− g1,1(t)}
T Γ−11 AiH1,i −
ˆ t
Ui
g1,0(u)
s0(β1, u)
AidM1,i(u)
]
+ op(1), (S9)
where the second equality follows by (S1).
Combining (S3) and (S9) leads to
n1/2
{
Sˆ1,mi(t)− S
δ-adj
1 (t)
}
=
n1/2
mn1
m∑
j=1
n1∑
i=1
[
Ai{1− Yi(t)}{1(T
∗(j)
i ≥ t)− S1(t | Oi; θˆ1)}
]
+
n1/2
n1
n1∑
i=1
Ai
[
φ11,i(t) + Yi(t) + {1− Yi(t)}(1− Ii)S1{t | Hi(t); θ} − S
δ-adj
1 (t)
]
(S10)
+op(1).
where
φ11,i(t) = {g1,2(t)− g1,1(t)}
T Γ−11 H1,i −
ˆ t
Ui
g1,0(u)
u0(β1, u)
dM1,i(u). (S11)
Similarly, for treatment group a = 0, define
φ0,i(t) = {g0,2(t)− g0,1(t)}
T Γ−10 H0,i −
ˆ t
Ui
g0,0(u)
u0(β0, u)
dM0,i(u), (S12)
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We have
n1/2
{
Sˆ0,mi(t)− S
δ-adj
0 (t)
}
=
n1/2
mn0
m∑
j=1
n∑
i=1
(1−Ai){1 − Yi(t)}[1(T
∗(j)
i ≥ t)− S0{t | Hi(t); θˆ}]
+
n1/2
n0
n∑
i=1
(1−Ai)
{
φ0,i(t) + Yi(t) + {1− Yi(t)}(1 − Ii)S0{t | Hi(t); θ} − S
δ-adj
0 (t)
}
(S13)
+op(1).
The martingale series approximation of ∆ˆτ,mi follows by plugging (S10) and (S13) into
n1/2
(
∆ˆτ,mi −∆
δ-adj
τ
)
= n1/2
[
Ψτ{Sˆ1,mi(t), Sˆ0,mi(t)} −∆
δ-adj
τ
]
=
1∑
a=0
ˆ τ
0
ψa(t)
{
Sˆa,mi(t)− Sa(t)
}
dt + op(1) =
(1+m)n∑
k=1
ξn,k + op(1),
where the ξn,k terms are given in (16) with φ10,i(t) = 0 and φ11,i(t) and φ0,i(t) given in
(S11) and (S12), respectively.
S2.2 Control-based Cox models
We focus on the treatment group a = 1. Under the control-based imputation model,
the MI estimator Sˆ1,mi(t) depends on not only the parameter estimator in the treatment
group but also the parameter estimator in the control group. Following the same steps
for (S4), we express the MI estimator as
n1/2
{
Sˆ1,mi(t)− S
δ-cb
1 (t)
}
=
n1/2
mn1
m∑
j=1
n∑
i=1
Ai{1− Yi(t)}[1(T
∗(j)
i ≥ t)− S1{t | Hi(t); θˆ}] (S14)
+
n1/2
n1
n∑
i=1
Ai
[
Yi(t) + {1− Yi(t)}(1− Ii)S1{t | Hi(t); θˆ} − S
δ-cb
1 (t)
]
, (S15)
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where under the imputation based on the control-based Cox model,
S1{t | Hi(t); θ} =


exp
{
−
´ t
Ui
λ1(u)e
βT
1
Xidu
}
, if Ai = 1, Ri = 1,
exp
{
−δ
´ t
Ui
λ0(u)e
βT
0
Xidu
}
, if Ai = 1, Ri = 2,
for t ≥ Ui.
By the counting process theory, we can further express n1/2n−11
∑n
i=1Ai{1−Yi(t)}(1−
Ii)S1{t | Hi(t); θˆ} in (S15) as
n1/2
n1
n∑
i=1
Ai{1− Yi(t)}(1− Ii)S1{t | Hi(t); θˆ}
=
n1/2
n1
n∑
i=1
Ai{1− Yi(t)}(1− Ii)1(Ri = 1) exp
{
−
ˆ t
Ui
λˆ1(u)e
βˆT
1
Xidu
}
+
n1/2
n1
n∑
i=1
Ai{1− Yi(t)}(1− Ii)1(Ri = 2) exp
{
−δ
ˆ t
Ui
λˆ0(u)e
βˆT
0
Xidu
}
=
n1/2
n1
n∑
i=1
Ai{1− Yi(t)}(1− Ii)1(Ri = 1) exp
{
−
ˆ t
Ui
λ1(u)e
βT
1
Xidu
}
+
n1/2
n1
n∑
i=1
Ai{1− Yi(t)}(1− Ii)1(Ri = 2) exp
{
−δ
ˆ t
Ui
λ0(u)e
βT
0
Xidu
}
+
n1/2
n1
n∑
i=1
Ai{1− Yi(t)}(1− Ii)1(Ri = 1)S1{t | Hi(t); θ}
[
−
ˆ t
Ui
eβ
T
1
Xi
{
λˆ1(u)− λ1(u)
}
du
]
+
[
1
n1
n∑
i=1
Ai{1− Yi(t)}(1− Ii)1(Ri = 1)S1{t | Hi(t); θ}
{
−
ˆ t
Ui
λ1(u)e
βT
1
XiXidu
}]
×n1/2
(
βˆ1 − β1
)
+
n1/2
n1
n∑
i=1
Ai{1− Yi(t)}(1− Ii)1(Ri = 2)S1{t | Hi(t); θ}
[
−δ
ˆ t
Ui
eβ
T
0
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{
λˆ0(u)− λ0(u)
}
du
]
+
[
1
n1
n∑
i=1
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λ0(u)e
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0
XiXidu
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×n1/2
(
βˆ0 − β0
)
. (S16)
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Denote
g˜1,0(t) = E
[
Ai{1− Yi(t)}(1− Ii)1(Ri = 1)S1{t | Hi(t); θ}e
βT
1
Xi
]
,
g˜1,1(t) = E
[
Ai{1− Yi(t)}(1− Ii)1(Ri = 1)S1{t | Hi(t); θ}
{ˆ t
Ui
λ1(u)e
βT
1
XiXTi du
}]
,
g˜1,2(t) = E
[
Ai{1− Yi(t)}(1− Ii)1(Ri = 1)S1{t | Hi(t); θ}
{ˆ t
Ui
λ1(u)e
βT
1
Xie1(β1, u)
Tdu
}]
,
g˜0,0(t) = E
[
Ai{1− Yi(t)}(1− Ii)1(Ri = 2)S1{t | Hi(t); θ}δe
βT
0
Xi
]
,
g˜0,1(t) = E
[
Ai{1− Yi(t)}(1− Ii)1(Ri = 2)S1{t | Hi(t); θ}
{
δ
ˆ t
Ui
λ0(u)e
δβT
0
XiXTi du
}]
,
g˜0,2(t) = E
[
Ai{1− Yi(t)}(1− Ii)1(Ri = 2)S1{t | Hi(t); θ}
{
δ
ˆ t
Ui
λ0(u)e
βT
0
Xie0(β0, u)
Tdu
}]
.
Then, we can express (S16) further as
=
n1/2
n1
n1∑
i=1
Ai{1− Yi(t)}(1− Ii)1(Ri = 1) exp
{
−
ˆ t
Ui
λ1(u)e
βT
1
Xidu
}
+
n1/2
n1
n1∑
i=1
Ai{1− Yi(t)}(1− Ii)1(Ri = 2) exp
{
−δ
ˆ t
Ui
λ0(u)e
βT
0
Xidu
}
+ {g˜1,2(t)− g˜1,1(t)}
T n1/2
(
βˆ1 − β1
)
−
n1/2
n1
n∑
j=1
ˆ t
Ui
g˜1,0(u)
s0(β1, u)
AjdM1,j(u)
+ {g˜0,2(t)− g˜0,1(t)}
T n1/2
(
βˆ0 − β0
)
−
n1/2
n1
n∑
j=1
ˆ t
Ui
g˜0,0(u)
s0(β0, u)
(1−Aj)dM0,j(u) + op(1)
=
n1/2
n1
n1∑
i=1
Ai{1− Yi(t)}(1− Ii)1(Ri = 1) exp
{
−
ˆ t
Ui
λ1(u)e
βT
1
Xidu
}
+
n1/2
n1
n1∑
i=1
Ai{1− Yi(t)}(1− Ii)1(Ri = 2) exp
{
−δ
ˆ t
Ui
λ0(u)e
βT
0
Xidu
}
+
n1/2
n1
n∑
i=1
[
{g˜1,2(t)− g˜1,1(t)}
T Γ−11 AiH1,i −
ˆ t
Ui
g˜1,0(u)
s0(β1, u)
AidM1,i(u)
]
+
n1/2
n0
n∑
i=1
[
{g˜0,2(t)− g˜0,1(t)}
T Γ−10 (1−Ai)H0,i −
ˆ t
Ui
g˜0,0(u)
s0(β0, u)
(1− Ai)dM0,i(u)
]
+ op(1)
=
n1/2
n1
n1∑
i=1
Ai{1− Yi(t)}(1− Ii)1(Ri = 1) exp
{
−
ˆ t
Ui
λ1(u)e
βT
1
Xidu
}
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+
n1/2
n1
n1∑
i=1
Ai{1− Yi(t)}(1− Ii)1(Ri = 2) exp
{
−δ
ˆ t
Ui
λ0(u)e
βT
0
Xidu
}
+
n1/2
n1
n∑
i=1
Ai
[
{g˜1,2(t)− g˜1,1(t)}
T Γ−11 H1,i −
ˆ t
Ui
g˜1,0(u)
s0(β1, u)
dM1,i(u)
]
+
n1/2
n0
n∑
i=1
(1− Ai)
[
{g˜0,2(t)− g˜0,1(t)}
T Γ−10 H0,i −
ˆ t
Ui
g˜0,0(u)
s0(β0, u)
dM0,i(u)
]
+ op(1). (S17)
Combining (S14) and (S17) leads to
n1/2
{
Sˆ1,mi(t)− S
δ-cb
1 (t)
}
=
n1/2
mn1
m∑
j=1
n∑
i=1
Ai{1− Yi(t)}
[
1(T
∗(j)
i ≥ t)− S1{t | Hi(t); θˆ}
]
+
n1/2
n1
n∑
i=1
(1−Ai)φ10,i(t)
+
n1/2
n1
n∑
i=1
Ai
[
φ11,i(t) + Yi(t) + {1− Yi(t)}(1− Ii)S1{t | Hi(t); θ} − S
δ-cb
1 (t)
]
+ op(1),
where
φ11,i(t) =
[
{g˜1,2(t)− g˜1,1(t)}
T Γ−11 H1,i −
ˆ t
Ui
g˜1,0(u)
s0(β1, u)
dM1,i(u)
]
(S18)
φ10,i(t) =
[
{g˜0,2(t)− g˜0,1(t)}
T Γ−10 H0,i −
ˆ t
Ui
g˜0,0(u)
s0(β0, u)
dM0,i(u)
]
. (S19)
Because the imputation mechanism for the censored control subjects is the same,
the martingale representation for Sˆ0,mi(t) remains the same as in (S13). Finally, we can
decompose ∆ˆτ,mi by the martingale representation
n1/2(∆ˆτ,mi −∆
δ-bc
τ ) =
(1+m)n∑
k=1
ξn,k + op(1),
where the ξn,k terms are given in (16) with φ11,i(t), φ10,i(t), and φ0,i(t) given in (S18),
(S19) and (S12), respectively.
For both the δ-adjusted and control-based Cox models, it follows by the martingale
CLT, n1/2
(
∆ˆτ,mi −∆
sen
τ
)
converges to a Normal distribution with mean zero and a finite
9
variance
V senτ,mi =
(1+m)n∑
k=1
E(ξ2n,k | Fn,k−1) =
1∑
a=0
(
σ2a,1 + σ
2
a,2
)
, (S20)
where sen denotes either δ-adj or δ-cb, and
σ20,1 =
1
p0
E
([ˆ τ
0
ψ0(t){(1− Ai)[φ10,i(t) + φ0,i(t) + Yi(t)
+ {1− Yi(t)}(1− Ii)Sa{t | Hi(t); θ}]− S
sen
a (t)}dt]
2)
σ21,1 =
1
p1
E
{(ˆ τ
0
ψ1(t)Ai[φ11,i(t) + Yi(t)
+ {1− Yi(t)}(1− Ii)Sa{t | Hi(t); θ} − S
sen
a (t)]dt
)}
,
σ2a,2 =
1
pam
V
[ˆ τ
0
ψa(t)1(Ai = a){1− Yi(t)}{1(T
∗(j)
i ≥ t)− Sa{t | Hi(t); θ}}dt
]
,
for a = 0, 1.
S3 Proof of Theorem 2
We provide the proof of Theorem 2, which draws on the martingale central limit theory
(Hall and Heyde, 1980) and the asymptotic property of weighted sampling of martingale
difference arrays (Pauly, 2011).
First, by the law of large numbers, we have
n1∑
k=1
ξ2n,k
=
n
n21
n1∑
i=1
(ˆ τ
0
ψ1(t)Ai [φ11,i(t) + Yi(t) + {1− Yi(t)}(1 − Ii)S1{t | Hi(t); θ} − S
sen
1 (t)] dt
)2
p
→
1
p1
E
{(ˆ τ
0
ψ1(t)Ai [φ11,i(t) + Yi(t) + {1− Yi(t)}(1 − Ii)S1{t | Hi(t); θ} − S
sen
1 (t)] dt
)2}
= σ21,1,
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and
(1+m)n1∑
k=n1+1
ξ2n,k
=
n
n21
n1∑
i=1
1
m2
m∑
j=1
[ˆ τ
0
ψ1(t)Ai{1− Yi(t)}[1(T
∗(j)
i ≥ t)− S1{t | Hi(t); θˆ}]dt
]2
p
→
1
p1m
E
(
var
[ˆ τ
0
ψ1(t)Ai{1− Yi(t)}[1(T
∗(j)
i ≥ t)− S1{t | Hi(t); θˆ}]dt | O1:n
])
= σ21,2,
as n→∞. Similarly, by the law of large numbers, we have
∑(1+m)n1+n0
k=(1+m)n1+1
ξ2n,k
p
→ σ20,1, and∑(1+m)n
k=(1+m)n1+n0+1
ξ2n,k
p
→ σ20,2. Therefore, we have
(1+m)n∑
k=1
ξ2n,k
p
→ V senτ,mi, (S21)
as n→∞.
Second, we show
max
1≤k≤(1+m)n
|ξn,k|
p
→ 0, (S22)
as n→∞. Toward this end, for any ǫ > 0,
P
(
max
1≤k≤n1
|ξn,k| > ǫ
)
≤ n1P (|ξn,k| > ǫ) = n1P
(
ξ4n,k > ǫ
4
)
≤
n2
n31ǫ
4
E
(ˆ τ
0
ψ1(t)Ai
[
S1{t | Hi(t); θˆ} − S
sen
1 (t)
]
dt
)4
→ 0,
where the second inequality follows from the Markov inequality, and the convergence
follows because the expectation term is bounded due to the natural range of the survival
functions. Similarly, we have
P
(
max
n1+1≤k≤(1+m)n1
|ξn,k| > ǫ
)
≤
n2
n31m
3ǫ4
E
{ˆ τ
0
ψ1(t)Ai[1(T
∗(j)
i ≥ t)− S1{t | Hi(t); θˆ}]dt
}4
→ 0,
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as n→∞. Therefore, P( max
1≤k≤(1+m)n1
|ξn,k| > ǫ)→ 0, as n→∞. Similarly, P( max
(1+m)n1+1≤k≤(1+m)n
|ξn,k| >
ǫ)→ 0, as n→∞. Then (S22) holds.
Third, we show
sup
n
E
(
max
1≤k≤(1+m)n
ξ2n,k
)
<∞. (S23)
For any n, by Assumption S1,
E
(
max
1≤k≤n1
ξ2n,k
)
≤ E
(
n1ξ
2
n,k
)
=
n
n1
E
(ˆ τ
0
[
ψ1(t)AiS1{t | Hi(t); θˆ} − S
sen
1 (t)
]
dt
)2
<∞,
and
E
(
max
n1+1≤k≤(1+m)n1
ξ2n,k
)
≤ E
(
nmξ2n,k
)
=
n
mn1
E
(ˆ τ
0
ψ1(t)Ai[1(T
∗(j)
i ≥ t)− S1{t | Hi(t); θˆ}]dt
)2
<∞.
Therefore, E(max1≤k≤(1+m)n1 ξ
2
n,k) ≤ E(max1≤k≤n1 ξ
2
n,k) +E(maxn1+1≤k≤(1+m)n1 ξ
2
n,k) <∞.
Similarly, E(maxn1(1+m)+1≤k≤n(1+m) ξ
2
n,k) <∞. Then (S23) follows.
Given the results in (S21) and (S22), the martingale CLT implies that
(1+m)n∑
k=1
ξn,k
d
→ N (0, V senτ,mi),
as n → ∞. Given the results in (S21), (S22), and (S23), Theorem 2.1 in Pauly (2011)
yields
sup
r
∣∣∣∣∣∣P

{(1 +m)n}1/2
(1+m)n∑
k=1
uk
{n(1 +m)}1/2
ξn,k ≤ r
∣∣∣∣∣∣O1:n

− Φ
( r
σ
)∣∣∣∣∣∣
p
→ 0, (S24)
as n→∞, where Φ(·) denotes the cumulative distribution function of the standard normal
distribution.
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Let WL = n
−1/2
∑(1+m)n
k=1 ξn,kuk. By Theorem 1 and (S24), we have
sup
r
∣∣∣P (n1/2WL ≤ r | O1:n)− P{n1/2 (∆ˆτ,mi −∆senτ ) ≤ r}∣∣∣ p→ 0, (S25)
as n→∞.
Lastly, to prove Theorem 2, it remains to show that
P
{
n1/2(WL −W
∗
L) | O1:n
} p
→ 0, (S26)
as n → ∞. To unify the notation for both treatment group, define Φ1,i(t) = φ11,i(t),
Φ0,i(t) = φ10,i(t) + φ0,i(t), Φˆ1,i(t) = φˆ11,i(t), and Φˆ0,i(t) = φˆ10,i(t) + φˆ0,i(t). The difference
between WL and W
∗
L can be decomposed to six parts,
n1/2(WL −W
∗
L) =
n(1+m)∑
k=1
n−1/2uk(n
1/2ξˆn,k − n
1/2ξn,k) =
1∑
a=0
3∑
l=1
Ral,n,
where
Ra1,n =
n∑
i=1
n1/2
na
ui1(Ai = a)
ˆ τ
0
ψa(t)
{
Sˆa,mi(t)− S
sen
a (t)
}
dt,
Ra2,n =
n∑
i=1
n1/2
na
ui1(Ai = a)
ˆ τ
0
ψa(t)
{
Φˆa,i(t)− Φa,i(t)
}
dt,
Ra3,n =
n∑
i=1
n1/2
na
ui1(Ai = a)
×
ˆ τ
0
ψa(t){1− Yi(t)}(1− Ii)
[
Sa{t | Hi(t); θˆ} − Sa{t | Hi(t); θ}
]
dt,
for a = 0, 1.
Given that the bootstrap weights satisfy E(u2k | O1:n) = 1, we have
E
(
R2a1,n|O1:n
)
=
n
n2a
naE(u
2
i )
[ˆ τ
0
ψa(t)
{
Sˆa,mi(t)− S
sen
a (t)
}
dt
]2
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=
n
na
[ˆ τ
0
ψa(t)
{
Sˆa,mi(t)− S
sen
a (t)
}
dt
]2
p
→ 0,
as n→∞, for a = 0, 1. Also, we have
E
(
R2a2,n|O1:n
)
=
n
n2a
n∑
i=1
1(Ai = a)
[ˆ τ
0
ψa(t)
{
Φˆa,i(t)− Φa,i(t)
}
dt
]2
p
→ 0,
as n→∞, for a = 0, 1, where the convergence follows by Assumption S1 and the results
in Section S1. Similarly, we have
E
(
R2a3,n|O1:n
)
=
n
n2a
na∑
i=1
1(Ai = a)
[ˆ τ
0
ψa(t){1− Yi(t)}(1− Ii)
{
Sa(t | Oi; θˆa)− Sa{t | Hi(t); θ}
}
dt
]2 p
→ 0,
as n→∞, for a = 0, 1. Therefore, for any ǫ > 0,
P{|Ra1,n| > ǫ | O1:n}
p
→ 0, P{|Ra2,n| > ǫ | O1:n}
p
→ 0, P{|Ra3,n| > ǫ | O1:n}
p
→ 0,
as n→∞, for a = 0, 1. Then we obtain (S26). The conclusion of Theorem 2 follows.
S4 Additional simulation results
Figure S1 displays the true and sensitivity survival curves under different sensitivity pa-
rameters. When the sensitivity parameter δ is set to be the true value 1.5, the sensitivity
survival curve overlaps with the true survival curve. Table S1 presents the simulation re-
sults for µ0,τ under CAR. Under CAR, the MI estimator is unbiased of the true estimand.
Rubin’s combining rule overestimates the true standard deviation with the relative bias
ranging from 12.26% to 12.91% for n = 500 and n = 1000. Consequently, the coverage
rates are 2% higher than the nominal level. On the other hand, the proposed wild boot-
strap procedure has small relative biases and close-to-nominal coverage rates for all n and
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Table S1: Simulation results for the RMST µ0,τ = 1.701 with the true sensitivity param-
eter δ = 1: point estimate, true standard deviation, relative bias of the standard error
estimator, coverage of interval estimate using Rubin’s method and the proposed wild
bootstrap method
Point est True sd Standard error Relative Bias Coverage (%)
(×102) (×102) (×102) (%) for 95% CI
n m Rubin WB Rubin WB Rubin WB
500 3 170.7 4.67 5.28 4.77 12.91 2.12 97.1 95.1
10 170.3 4.64 5.23 4.78 12.80 3.05 97.2 94.3
1000 3 170.3 3.33 3.74 3.38 12.27 1.55 96.8 94.2
10 170.2 3.30 3.71 3.37 12.26 2.23 96.4 94.5
m. Table S2 presents the simulation results for sensitivity analysis of µδ-adj1,τ . The same
discussion in Section 5 applies here.
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Table S2: Simulation results for the true estimand µδ-adj1,τ = 1.755 with the true sensitivity
parameter δ = 1.5: point estimate, true standard deviation, relative bias of the standard
error estimator, coverage of interval estimate using Rubin’s method and the proposed
wild bootstrap method
Point est True sd
Standard error Relative Bias Coverage (%)
(×102) (%) for 95% CI
n δ m (×102) (×102) Rubin WB Rubin WB Rubin WB
0.5
5 186.6 4.70 5.32 4.80 13.18 2.13 44.7 36.4
10 186.3 4.71 5.27 4.83 12.08 2.63 47.1 40.4
1
5 180.2 4.69 5.29 4.75 12.69 1.14 88.1 83.6
10 179.9 4.70 5.24 4.77 11.58 1.54 90.0 86.0
500
1.5
5 175.9 4.66 5.24 4.75 12.31 1.79 97.2 95.0
10 175.7 4.67 5.20 4.77 11.17 2.05 97.3 95.6
2
5 172.9 4.63 5.19 4.76 12.12 2.83 93.9 91.4
10 172.6 4.65 5.16 4.78 10.92 2.94 94.0 90.9
2.5
5 170.6 4.60 5.16 4.78 11.99 3.83 88.6 82.7
10 170.3 4.62 5.12 4.80 10.81 3.92 86.3 82.1
0.5
5 186.2 3.28 3.76 3.40 14.39 3.43 18.0 12.6
10 186.2 3.31 3.73 3.39 12.63 2.51 17.3 13.3
1
5 179.8 3.27 3.73 3.36 14.36 2.82 81.2 75.1
10 179.8 3.30 3.70 3.35 12.25 1.66 81.2 75.4
1000
1.5
5 175.5 3.25 3.70 3.36 13.69 3.18 96.8 94.7
10 175.5 3.29 3.67 3.36 11.68 2.10 97.0 94.0
2
5 172.5 3.24 3.67 3.37 13.25 4.00 90.2 86.1
10 172.5 3.27 3.64 3.37 11.30 2.95 90.0 86.1
2.5
5 170.2 3.22 3.64 3.38 13.00 4.89 71.2 65.5
10 170.1 3.26 3.62 3.38 11.07 3.85 70.0 65.4
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Figure S1: Sensitivity analysis: the true and sensitivity survival curves under different
sensitivity parameters δ ∈ {0.5, 1, 1.5, 2, 2.5}: the black line is the true survival curve with
δ = 1.5.
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